A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions Full Text
JACC - Journal of the American College of Cardiology, 04/20/2012
Carrie D et al. –The Cre8 stent in de novo lesions showed significantly lower in–stent LLL at 6 months than the Taxus Liberte stent did, with a trend toward better 12–month clinical safety and efficacy results.
